GEN - Genetic Engineering and Biotechnology News

Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, in a deal that would expand the ...
MedPage Today

New Biomarker May Improve Diagnosis of Hypercortisolism

At ENDO 2026, the annual meeting of the Endocrine Society, researchers reported that measuring adrenocorticotropic hormone ...

Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...

Vertex sees over $5 billion peak sales potential from Crinetics assets

Vertex Pharmaceuticals Incorporated VRTX on Monday agreed to acquire Crinetics Pharmaceuticals Inc. CRNX for $85 per share in ...
Fierce Pharma

Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B

The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...
Las Vegas Sun

Vertex to Acquire Crinetics Pharmaceuticals

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.: Vertex to Acquire Crinetics Pharmaceuticals

Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - PALSONIFY, Crinetics' recently launched, first ...
Medindia

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 ...